Clinical trialPhase 1

MSK-DA01 (bemdaneprocel) phase 1 in advanced Parkinson's disease

NCT04802733

Open-label phase 1 safety and tolerability study of MSK-DA01 (bemdaneprocel), sponsored by BlueRock Therapeutics, in 12 patients with advanced Parkinson's disease. Results published by Tabar et al., Nature 2025 (PMID 40240592).

1 news item

News about this trial

Scales

Identifiers

NCT: NCT04802733

Original sources

ClinicalTrials.gov · NCT04802733 ↗

Details

Phase: Phase 1
Status: Completed

A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.